ZINACEF (cefuroxime sodium) by R-Pharm US is mechanism of action cefuroxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Approved for including pneumonia, caused by streptococcus pneumoniae, haemophilus influenzae (including ampicillin-resistant strains) and 3 more indications. First approved in 1983.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
ZINACEF (cefuroxime sodium) is a second-generation cephalosporin antibiotic administered by injection that treats serious bacterial infections including pneumonia, meningitis, and infections caused by ampicillin-resistant Haemophilus influenzae and other gram-negative and gram-positive organisms. It works as a bactericidal agent by inhibiting bacterial cell wall synthesis and demonstrates activity against beta-lactamase-producing bacteria.
As an LOE-approaching product with high competitive pressure (30/100), brand teams face declining market opportunity and likely contraction in headcount and resources.
Mechanism of Action Cefuroxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefuroxime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria.
Worked on ZINACEF at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moZINACEF offers limited career growth potential due to LOE-approaching status and zero linked job openings; roles are concentrated in institutional/hospital sales and reimbursement management rather than innovation-focused functions. Career trajectory on this product favors those seeking stable, transactional work in mature accounts over those pursuing advancement into senior strategy or development roles.